

UTAH MEDICAL PRODUCTS INC

Form 8-K

October 23, 2018

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): October 23, 2018

UTAH MEDICAL PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

<u>Utah</u> (State or other jurisdiction of incorporation or organization)	<u>000-12575</u> (Commission File Number)	<u>87-0342734</u> (IRS Employer Identification No.)
-------------------------------------------------------------------------------	----------------------------------------------	--------------------------------------------------------

7043 South 300 West <u>Midvale, Utah</u> (Address of principal executive offices)	<u>84047</u> (Zip code)
-----------------------------------------------------------------------------------------	----------------------------

Registrant's telephone number, including area code: Phone: (801) 566-1200

n/a  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

---

ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2018 and forward-looking statements relating to 2018 and beyond as presented in a press release dated October 23, 2018. The information in this report shall be deemed incorporated by reference into any registration statement heretofore or hereafter filed under the Securities Act of 1933, as amended, except to the extent that such information is superseded by information as of a subsequent date that is included in or incorporated by reference into such registration statement. The information in this report shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS

The following is filed as an exhibit to this report:

Exhibit Number*	Title of Document	Location
Item 99.1	Financial information for Utah Medical Products, Inc. for the three and nine months ended September 30, 2018 and forward-looking statements relating to 2018 and beyond as presented in a press release dated October 23, 2018.	This filing

---

\*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UTAH MEDICAL PRODUCTS, INC.

Dated: October 23, 2018 By: /s/ Kevin L. Cornwell  
Kevin L. Cornwell, Chief Executive Officer